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Resveratrol inhibits benzo[a]pyrene–DNA adduct formation in
human bronchial epithelial cells
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Resveratrol (trans-3,40 ,5-trihydroxystilbene), a phytoalexin present in various plants and foods, has in several in vitro and in vivo studies
demonstrated cancer chemopreventive and chemotherapeutic potential. We investigated the in vitro effect of resveratrol on
benzo[a]pyrene (B[a]P) -induced DNA adducts in human bronchial epithelial cells. This was compared to the effect of resveratrol on
the expression of the cytochrome P450 (CYP) genes CYP1A1 and CYP1B1 and the formation of B[a]P metabolites. Exposure of
BEAS-2B and BEP2D cells to B[a]P and increasing concentrations of resveratrol resulted in a dose- and time-dependent inhibition of
DNA adduct formation quantified by 32P-postlabelling. Supporting this result, resveratrol was shown to inhibit CYP1A1 and CYP1B1
gene expression, as measured by real-time reverse transcriptase—polymerase chain reaction. Also, a significant correlation was found
between the number of DNA adducts and the mRNA levels of these genes. Using HPLC analysis, a concomitant decrease in the
formation of B[a]P-derived metabolic products was detected. In conclusion, these data lend support to a chemopreventive role of
resveratrol in polycyclic aromatic hydrocarbon-induced carcinogenesis.
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Lung cancer is among the most frequent causes of cancer death in
the western world today and the global incidence is increasing
(Bilello et al, 2002; Kuper et al, 2002). Lung cancer is therefore
expected to continue to have a major impact on human health
throughout the next decades. The role of tobacco smoke as a major
aetiologic factor in this malignancy is well established. Urban air
pollution and occupational exposure may also increase the risk of
lung cancer (Bilello et al, 2002). Approximately 25 –30% of adults
in western populations are active smokers, and the number is
increasing in developing countries (Peto et al, 1996). The fact that
in the US and in some European countries, more than 40% of new
lung cancer cases occur in former smokers, merits increased focus
on studies to prevent the development of the disease (Tong et al,
1996).
Polycyclic aromatic hydrocarbons (PAH) are potent tobacco-
smoke carcinogens and occur in complex mixtures in the
environment (Hecht, 2003). Benzo[a]pyrene (B[a]P) is a major
constituent of these mixtures and has been widely used as a model
compound in studies of PAH-induced carcinogenesis. B[a]P is
metabolically activated by enzymes in the cytochrome P450 (CYP)
system to reactive electrophilic diolepoxides that are capable of
binding to DNA (Denissenko et al, 1996; Hecht, 2003). CYP1A1
and CYP1B1, which are major PAH bioactivating enzymes, are
induced by PAH in human lung tissue (Ding and Kaminsky, 2003).
Thus, inhibition of PAH bioactivation and subsequent reduction of
DNA adduct formation may be an important step in the prevention
of smoking associated lung carcinogenesis.
Although the confounding effect of alcohol drinking on lung
cancer development is controversial and may be dose-dependent,
epidemiological studies have indicated that wine consumers may
have a lower risk of developing this cancer compared with
consumers of other beverages (Prescott et al, 1999; De Stefani et al,
2002). Resveratrol (trans-3,40,5-trihydroxystilbene), a diphenolic
phytoalexin, is present in high concentrations in red wines, as well
as in berries and nuts (Fremont, 2000). In addition to a possible
beneficial effect of resveratrol on the risk of coronary heart disease
(Renaud and de Lorgeril, 1992; Hung et al, 2000), resveratrol has
been suggested to have cancer chemopreventive potential by
interfering with many cellular pathways. The compound has been
shown to block tumorigenesis in a mouse model and to inhibit
tumour growth and neovascularisation in rodents (Jang et al, 1997;
Carbo et al, 1999; Kimura and Okuda, 2001). Besides the
antiproliferative effects, induction of apoptosis has been demon-
strated both in vitro and in vivo (Carbo et al, 1999; Mgbonyebi
et al, 1998; Ahmad et al, 2001; Narayanan et al, 2003). Resveratrol
has also been shown to modulate the expression of genes involved
in the bioactivation of PAH (Ciolino and Yeh 1999; Mollerup et al,
2001).
In the present study, the effect of resveratrol on B[a]P-derived
DNA adducts was investigated in the immortalised human
bronchial epithelial cell lines BEAS-2B and BEP2D. Quantitative
analysis of DNA adducts was compared to the effect of resveratrol
on the expression of CYP1A1 and CYP1B1 and on the formation of
B[a]P-derived metabolites. A time- and dose-dependent inhibition
of B[a]P-induced DNA adduct formation by resveratrol was found.
This correlated with the levels of CYP1A1 and CYP1B1 expression
and concentration of B[a]P metabolites. A long-term effect of
resveratrol on B[a]P-metabolite formation was found.
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MATERIAL AND METHODS
Chemicals
Unless otherwise stated all chemicals were from Sigma (St Louis,
MO, USA).
Cell lines and culture conditions
The immortalised human bronchial epithelial cell lines BEP2D and
BEAS-2B were kindly provided by Drs JC Willey and CC Harris,
respectively. The cells were maintained in LHC-9 medium
(BioFluids, Rockville, MD, USA) containing 0.45mg ml1 bovine
serum albumin, at 371C in a humidified 5% CO2 atmosphere. In
the experiments, 80–90% confluent cell cultures were treated with
0–50 mM resveratrol (Sigma, St Louis, MO, USA) in the presence of
1 mM B[a]P (Sigma) for 24–120 h. After incubation, the cell culture
medium was collected and kept at 201C until further analysis
(high-performance liquid chromatography, HPLC). The plates
were washed with cold phosphate-buffered saline, treated with
trypsin (Sigma) and the cell pellet stored at 701C for RNA
isolation and DNA adduct measurements. Solutions of resveratrol
and B[a]P were made in 100% DMSO. During the experiments, the
final concentration of DMSO was 0.1%. Experiments were
performed in replicates of three and repeated several times, with
similar results.
Aromatic/hydrophobic DNA adducts
DNA was extracted from cell pellets. Aromatic/hydrophobic DNA
adducts were quantified by 32P-postlabelling analysis with the
nuclease P1 modification as described previously (Phillips et al,
1990). Each sample was measured in parallel.
Quantitative real-time reverse transcription – polymerase
chain reaction (RT– PCR)
Total RNA was extracted from cells by the TRIzol reagent
(Invitrogen). mRNA was reverse transcribed by the aid of the 1st
Strand cDNA Synthesis Kit for RT-PCR (AMV) using random
primers (Roche Diagnostics, Basel, Switzerland). PCR primers
(DNA Technology, Science Park Aarhus, Denmark) were designed
to span introns to avoid amplification from traces of possible DNA
contamination in the RNA isolation. Primers were checked for
specificity by Blast search CYP1A1 forward, 50-CAT CCC CCA CAG
CAC AAC A-30; CYP1A1 reverse, 50-CAG GGG TGA GAA ACC GTT
CA-30; CYP1B1 forward, 50-CTG GAT TTG GAG AAC GTA CCG-30;
CYP1B1 reverse, 50-TGA TCC AAT TCT GCC TGC AC-30; b-actin
forward, 50-GCG AGA AGA TGA CCC AGA TCA-30; b-actin
reverse, 50-GAT AGC ACA GCC TGG ATA GCA A-30. These primer
pairs give rise to PCR products of 152, 143, and 76 bp, respectively.
During establishment of the real-time PCR method, PCR products
were subjected to gel electrophoresis to ensure purity and correct
fragment size. Quantitative analysis of the specific expression of
various genes was performed by real-time PCR, on an ABI PRISM
5700 (Applied Biosystems, Foster City, CA, USA) with SYBRgreen I
(40 cycles of 951C 15 s, 601C 1 min). The amount of target cDNA in
each sample was established by determining a fractional PCR
threshold cycle number (Ct), and estimated by interpolation from a
standard curve. The standard curve was made from known
amounts of the corresponding product with the same primer sets,
and was run on each PCR plate. The expression levels of CYP1A1
and CYP1B1 were normalised to the expression of the b-actin gene.
High-performance liquid chromatography
For the analysis of B[a]P metabolites, culture medium (3 ml) from
exposed cells was collected and stored at 201C until further
processing. The medium was diluted to 10 ml in H2O, applied to a
preconditioned (5 ml methanol and 10 ml water) Sep-Pak C18
cartridge (Millipore Corporation, Milford, MA, USA), followed by
a wash with H2O (10 ml), and eluted with 100% methanol (5 ml).
The methanol eluate was evaporated to dryness at 451C under a
nitrogen stream and resolubilised in 100ml of 100% methanol.
HPLC separation of B[a]P metabolites was performed on a Nova-
Pak C18 3.9 150 mm2 column (Waters, Milford, MA, USA) with a
Waters 625 LC System, equipped with a LC 240 fluorescence
detector (Perkin-Elmer, Beaconsfield, UK). The B[a]P metabolites
were separated by a linear gradient of 30–100% methanol in H2O
for 40 min. For the quantitative determination of B[a]P tetrols, the
following fluorescence conditions were used: 0 min, ex 380/em 431;
0.5 min, ex 341/em 381; 20 min, ex 253/em 410; 27 min, ex 380/em
431. The concentration of B[a]P metabolite standards was
determined by ultraviolet absorbance of the compounds dissolved
in ethanol and using extinction coefficients from the NIH
Chemical Carcinogen Repository (Midwest Research Institute,
Kansas City, MO, USA).
Statistical analysis
The effect of resveratrol on the formation of DNA adducts, CYP
expression and concentration of B[a]P-tetrol I-1 was investigated
in four separate linear regression models. As cell line affected the
level of response variables, it was included as a variable in all
models. To achieve uniform variance throughout the data set, the
response variables were log transformed in the analyses. Exposure
time was considered a class variable. The concentration of
resveratrol was treated as a continuous variable. The global model
included resveratrol concentration, length of exposure, and the
intercept between these two factors, and a backward stepwise
method with 5% alpha level to exclude insignificant parameters.
All analyses were carried out in R version 1.8.0 (Anon, 2003).
RESULTS
Effect of resveratrol on DNA adducts
The immortalised human epithelial cell lines BEAS-2B and BEP2D
were incubated with a combination of 1 mM B[a]P and increasing
amounts of resveratrol for 24 or 72 h. Treatment of both cell lines
with B[a]P in the absence of resveratrol resulted in a significant
formation of DNA adducts, and the level was higher in BEP2D than
in BEAS-2B (Figure 1). Cotreatment with 10–50 mM resveratrol
resulted in a dose-dependent inhibition in the number of DNA
adducts (F¼ 50.3, df¼ 1, Po0.0001, for both lines combined).
Incubation of BEAS-2B with 1 mM B[a]P alone resulted in 26.1 and
80.9 adducts 108 nucleotides after 24 and 72 h, respectively. At
10mM resveratrol, these levels were reduced by 67 and 62% (Figure
1A and 1B). In BEP2D cells incubated with 1 mM B[a]P, a level of
95.5 adducts 108 nucleotides was measured after 24 h, which
increased to 652.1 after 72 h (Figure 1C and 1D). In the presence of
10mM resveratrol, a 51% decrease was found after 24 h (Figure 1C).
At 10 mM resveratrol, the high number of adducts formed after 72 h
was reduced by 70% (Figure 1D). The inhibiting effect of
resveratrol was more pronounced after 72 than 24 h (F¼ 5.1,
df¼ 1, P¼ 0.047, for both cell lines combined).
Quantitative real-time RT–PCR
The expression levels of CYP1A1 and CYP1B1 mRNA were
determined in the human bronchial epithelial cell lines by real-
time RT–PCR and normalised to the expression of b-actin. Data
for BEAS-2B are shown in Figure 2. The BEP2D cells responded to
B[a]P and resveratrol exposure similarly as reported in Mollerup
et al (2001). CYP1A1 mRNA increased from 24 to 72 h in both cell
lines exposed to B[a]P (F¼ 35.3, df¼ 1, P¼ 0.0001). Cotreatment
with increasing concentrations of resveratrol resulted in a
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decreased level of CYP1A1 mRNA (F¼ 39.3, df¼ 1, Po0.0001, for
both cell lines combined). In BEAS-2B cells, 10 mM resveratrol
reduced CYP1A1 by 56 and 70% after 24 and 72 h, respectively. For
50 mM resveratrol, the reduction was 97% at both time points
(Figure 2A and 2B). In BEAS-2B cells, CYP1B1 mRNA appeared to
be maximally induced by B[a]P after 24 h (data not shown).
Increasing concentrations of resveratrol also inhibited CYP1B1
gene expression dose dependently at both time points (both cell
lines combined: F¼ 7.7, df¼ 1, P¼ 0.0001).
The expression levels of CYP1A1 and CYP1B1 were significantly
related to the number of DNA adducts (F¼ 19.7, df¼ 1, P¼ 0.001,
and F¼ 8.2, df¼ 1, P¼ 0.01, for CYP1A1 and CYP1B1, respec-
tively). However, both genes are transcriptionally activated by the
aryl hydrocarbon receptor (AHR), and the mRNA levels of the two
genes were found to be strongly correlated.
Effect of resveratrol on the formation of B[a]P metabolites
B[a]P is metabolised into the carcinogenic diolepoxides, BPDE-I
and BPDE-II. The effect of resveratrol on the formation of B[a]P-
tetrols was measured by fluorescence HPLC in the cell culture
medium. The cells were treated with 1 mM B[a]P and 0– 50mM
resveratrol for 24, 48, 72 or 120 h. The hydrolysis product of the
ultimate carcinogen BPDE-I, B[a]P-tetrol I-1, was found as the
most abundant form. In the absence of resveratrol, the formation
of B[a]P-tetrol I-1 increased steadily during the 120-h period
(Figure 3). With the addition of resveratrol, the formation of the
tetrol was inhibited in a dose-dependent manner throughout the
incubation period in both cell lines (F¼ 210.1, df¼ 1.58,
P¼ 0.0001). A time effect was found, where the effect of resveratrol
increased with incubation time (F¼ 4.4, df¼ 3.58, P¼ 0.003). For
BEAS-2B, incubation in the presence of 1 mM B[a]P led to an
increase from 0.5 nM B[a]P-tetrol I-1 (24 h) to 18.5 nM B[a]P-tetrol
I-1 (120 h). Cotreatment with 10 mM resveratrol reduced the level by
60% after 24 h and 71% after 120 h. At 50 mM resveratrol, the
concentration of the tetrol was below detection limits at all time
points (Figure 3A). The BEP2D cells showed a similar pattern of
induction and inhibition, while the concentration of B[a]P-tetrol
I-1 reached higher levels than in the BEAS-2B. In BEP2D, a
concentration of 57.0 nM of the tetrol was measured after 120 h
without resveratrol. At 50mM resveratrol, virtually no B[a]P-tetrol
I-1 was detectable (Figure 3B).
The other tetrols (B[a]P-tetrol I-2, B[a]P-tetrol II-1, and B[a]P-
tetrol II-2) showed similar trends or were below detection limits.
DISCUSSION
The interest in chemicals effective in the reduction or inhibition of
cancer is increasing and chemoprevention via nontoxic agents
would greatly benefit public health. Plant-derived foods contain
thousands of chemically dissimilar phytochemicals, many of which
have been studied in vitro and in vivo to determine their effects on
cancer risk and their mechanism of action. DNA adducts may be
considered a risk factor for lung cancer, and their measurement
can be used as a biomarker for PAH exposure (Phillips et al, 1988;
Mollerup et al, 1999; Wiencke et al, 1999). In this study, we
investigated the effect of resveratrol on premutagenic B[a]P– DNA
adducts in the human bronchial epithelial cell lines BEAS-2B and
BEP2D. We used 32P-postlabelling to quantify B[a]P–DNA
adducts. Exposure to 1 mM of B[a]P led to a significant induction
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Figure 1 B[a]P–DNA adducts measured by 32P-postlabelling in BEAS-2B (A and B) and BEP2D cells (C and D). The cells were treated with 1mM B[a]P
and increasing amounts of resveratrol as indicated and incubated for 24 h (A and C) and 72 hr (B and D). Columns represent the mean of two
measurements from a representative assay. *Not performed.
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of adducts, which was inhibited by cotreatment with 10– 50mM
resveratrol in a time- and dose-dependent manner. The present
report shows that resveratrol can inhibit the formation of a
genotoxic end product of a tobacco-smoke carcinogen in human
bronchial epithelial cells. The level of DNA adducts differed
between the cell lines, being higher in BEP2D than in BEAS-2B. A
concentration of 10 mM resveratrol showed strong inhibitory effects
on the level of DNA adducts and halved the number of adducts in
both BEAS-2B and BEP2D after treatment for 24 h. At 50 mM
resveratrol, an almost complete inhibition of DNA adduct
formation in both cell lines for up to 72 h was observed. This
indicates that resveratrol is a competent inhibitor of B[a]P adduct
formation irrespective of the bioactivating capacity of the cell line.
In support of our data, Revel et al (2003) found by a
semiquantitative immunohistochemical method that resveratrol
inhibited lung B[a]P– DNA adduct formation in mice.
Resveratrol was found to exhibit a strong dose-dependent
inhibition of both CYP1A1 and CYP1B1 expression. This is in
accordance with previous data, where resveratrol inhibited the
expression levels of CYP1A1 and CYP1B1 in BEP2D cells exposed
to B[a]P for 24 h (Mollerup et al, 2001). In this study, we show that
resveratrol had a long-lasting transcriptional inhibitory effect on
both genes, which correlated with a reduced capacity to metabolise
B[a]P. We have previously shown a significant relationship
between CYP1A1 expression and the level of DNA adducts in
normal human lung tissue (Mollerup et al, 1999). Similarly, in this
in vitro assay the inhibition of CYP1A1 and CYP1B1 expression by
resveratrol could significantly explain the reduction in the number
of DNA adducts. Decreased levels of CYP1A1 mRNA and protein
activity and modulation of CYP1B1 expression by resveratrol has
also been shown in other cell types (Ciolino and Yeh, 1999; Chang
et al, 2000; Lee and Safe, 2001). Various molecular interactions
have been proposed to be responsible for these inhibitory effects of
resveratrol. Casper et al (1999) reported that resveratrol inhibited
CYP1A1 expression by functioning as an aryl hydrocarbon
receptor (AHR) antagonist. This is in contrast to studies by
Ciolino and Yeh (1999) showing that resveratrol does not replace
TCDD from AHR, but prevents the transformation of AHR to an
activated nuclear DNA binding form. An AHR-independent post-
transcriptional pathway has also been suggested, in which
resveratrol increases the rate of CYP1A1 mRNA degradation (Lee
and Safe, 2001). In addition, a direct inhibition of CYP1A1
enzymatic activity in cell free extracts has been shown (Chun et al,
1999; Ciolino and Yeh, 1999).
After exposure to B[a]P, the most abundant metabolite
identified in the cell culture medium was B[a]P-tetrol I-1, a
hydrolysis product of the ultimate carcinogen BPDE-I. The
formation of the tetrol was inhibited dose dependently by
resveratrol from 24 to 120 h. However, in the absence of resveratrol
the rate B[a]P-tetrol I-1 formation increased throughout the same
incubation period. These results indicate a prolonged inhibitory
effect of resveratrol on PAH metabolism and the inhibiting effect
was found to be more pronounced over time.
The total beneficial effect of resveratrol may be a result of e
ffects on various cell systems, and the compound may inhibit all of
the initiation, promotion, and progression phases of carcinogen-
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relative to the expression of b-actin in BEAS-2B cells. Cells were treated
with 1 mM B[a]P and increasing amounts of resveratrol for 24 h (A) and
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esis. The ring structure of resveratrol makes it an antioxidant
(Ray et al, 1999). In addition to CYP1A1 and CYP1B1, resveratrol
may affect mRNA levels of genes involved in phase II
drug-metabolising enzymes (Mollerup et al, 2001). Resveratrol
has been shown to disturb cell cycle regulation and induce
apoptosis. Both p53-dependent and -independent induction of
apoptosis by resveratrol has been shown in various cell
lines (Huang et al, 1999; Ahmad et al, 2001; Mahyar-Roemer
et al, 2001; Narayanan et al, 2003). Apoptosis was also shown
to be initiated in a tumour cell inoculation assay in rats
(Carbo et al, 1999). Resveratrol also inhibited cell growth
and modulated cell cycle in several human cancer cells
(Mgbonyebi et al, 1998; Ferry-Dumazet et al, 2002). An
antipromotion activity of the compound by inhibiting cyclo-
oxygenase, as well as DNA polymerase and ribonucleotide
reductase has been reported (Subbaramaiah et al, 1998; Fontecave
et al, 1998; Sun et al, 1998).
Modulation of PAH procarcinogen activation either by prevent-
ing the induction of metabolising enzymes or by inhibiting enzyme
activity may be an important step in the chemoprevention of
cancer and, in particular, lung cancer. This work shows that
resveratrol can inhibit the formation of DNA adducts in human
bronchial epithelial cells in vitro and supports a role for resveratrol
as a chemopreventive dietary constituent. Further studies are
needed to clarify whether this effect can be reproduced in an in
vivo model of lung carcinogenesis.
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